Hepatitis C-Virus Infection and Risk of Coronary Heart Diseases
Clinical Medicine Research
Volume 3, Issue 2, March 2014, Pages: 44-49
Received: Jan. 25, 2014; Accepted: Apr. 8, 2014; Published: Apr. 10, 2014
Views 3276      Downloads 135
Authors
Amin M. Abdel Baki, Department of Tropical Medicine, National Hepatology and Tropical Medicine Research Institute, Cairo, Egypt
Nashwa A. Zaky, Department of Clinical Pathology, National Hepatology and Tropical Medicine Research Institute, Cairo, Egypt
Article Tools
Follow on us
Abstract
Background: The world Health Organization has declared hepatitis C a global health problem, with approximately 3 % of the worldﹶs population. HCV infection was associated with a high risk of CHD. Hs-CRP and fibrinogen was considered as markers of coronary artery disease, their elevation correlated with incidence of CAD, However Apo A deficiency predict future risk of CAD. Aim: To study correlation between HCV infections and marker risk factors of coronary heart disease in different stages of liver disease. Patients & Method: Forty three chronic HCV patients were recruited at specialized hepatology clinic in National Hepatology and Tropical Medicine Research Institute (NHTMRI),Cairo; they were classified into 3 groups according to Child – Pugh score (A, B, C), 42 % were Child class A, 28 % Child B and 30 % Child C, age from 20 to 80 years. 15 healthy subjects served as control group. Detection of the following tests occurred for both groups: Liver function tests: ALT, AST, ALP, total protein, albumin, bilirubin, GGT and AFP. Ultra sensitive CRP, fibrinogen, apoprotein A and Lipid profile: Total Cholesterol, triglyceride, HDL-C, LDL-C, and Total Lipid. Results: the data obtained from results show that :liver enzymes AST, ALT, total bilirubin, albumin, total protein and INR levels were significantly different between groups and control (p< 0.05), Alkaline phosphates, GGT and AFP levels were not differing significantly in study groups and control (p> 0.05). Cardiac enzymes; CK and LDH levels were not significantly different between groups and control (p> 0.05). The APO A levels were not differs significantly in study groups and controls (p> 0.05). The fibrinogen andhs-CRP levels in the patients appeared to be significantly higher than those in the healthy controls (p< 0.05). Conclusion: hs-CRP and fibrinogen may be considered as a CHC progression prognostic factor, Evidence indicates that hepatitis C virus (HCV) have a key role in coronary heart disease.
Keywords
Fibrinogen, Cardiovascular Disease, Hs-CRP, Hepatitis C Virus, APO A
To cite this article
Amin M. Abdel Baki, Nashwa A. Zaky, Hepatitis C-Virus Infection and Risk of Coronary Heart Diseases, Clinical Medicine Research. Vol. 3, No. 2, 2014, pp. 44-49. doi: 10.11648/j.cmr.20140302.18
References
[1]
Mohamed M.K. (2004). Epidemiology of HCV in Egypt 2004. The Afro-Arab Liver Journal 3(2): 41-52.
[2]
Fallahian F, Najafi A. (2011). Epidemiology of hepatitis C in the Middle .EastSaudi J Kidney Dis Transpl.; 22(1):1-9.
[3]
Vassalle C, Masini S, Bianchi F, Zucchelli GC. (2004). Evidence for association between Hepatitis C virus seropositivityu and coronary artery disease.Heart 90:565-566.
[4]
Vassilios Papadopoulos1, Zafiris Kartasis2, Konstantinos Mimidis1, Stephanos Papantoniou1, et al., (2000) .Evaluation of haemostasis impairment in early stages of liver cirrhosis: a clinical study. J Mol Diagn. 2(3): 158–166.
[5]
Guido M, Mangia A, Faa G; (2011). Chronic viral hepatitis: the histology report. Dig Liver Dis.; 43 Suppl 4:S331-43.
[6]
Gumber, SC. and Chopra, S. (1995): Hepatitis C: a multifaceted disease. Review of extra hepatic manifestations. Ann Intern Med. 123:615-620.
[7]
El-Serag, HB., Hampel, H. and Yeh, C. (2002): Extra hepatic manifestations of hepatitis among United States male veterians. J Hepatol. 36:1439-45.
[8]
Forde K A, Kevin H, Andrea B T, Stacey T, et al., (2012). Risk of myocardial infarction associated with chronic hepatitis C virus infection: a population-based cohort study. J Viral Hepat. 2012 April; 19(4): 271–277.
[9]
Butt, AA, Xiaoqiang, W., Budoff, M., Leaf, D., Kuller, LH, Justice, AC. (2009).HepatitisC virus and the risk of coronary disease. Clin Infect Dis; 49:225-232.
[10]
Bukh, J., Miller, RH., Purcell, RH., (1995).Biology and genetic heterogeneity of hepatitis C virus. Clin Exp Rheumatol. Nov- Dec;13 Suppl 13:S3-7.
[11]
Di Bisceglie AM, Stoddard AM, Dienstag JL, et al.,(2011). Excess mortality in patients with advanced chronic hepatitis C treated with longterm peginterferon. Hepatology; 53(4):1100-1108.
[12]
Lengyel G, Aszalos Z, Tulassay Z. (2007). Hepatitis C viral infection and depression. Orv Hetil. Jan 7; 148(1):11-5.
[13]
Darwish, N.M., abas, M.o., Abdel Fattah, M.F. and Darwish, M.A. (1992). Hepatitis C virus infection in blood donoers in Egypt. The journal of Egyptian public health association vol. LXV II, No.34, page 224-232.
[14]
Osman E E, Esmat G, Adela M G, et al., (2011). Factors affecting recurrence of hepatitis C virus in adult living donor liver transplantation among egyptian patients. Macedonian Journal of Medical Sciences doi:10.3889/MJMS.1857-5773.2011.0144.
[15]
Suman B S, Seema G, Abhinav V and Sridhar D, (2008). Hs-CRP and oxidative stress in young cad patients: a pilot study. Indian Journal of Clinical Biochemistry, / 23 (4) 334-336.
[16]
Arcari CM, Nelson KE, Netski DM, Nieto FJ, Gaydos CA. No association between hepatitis C virus seropositivity and acute myocardial infarction. Clin Infect Dis. 2006; 43:e53–6.
[17]
Rodriguez-Inigo E, Casqueiro M, Bartolome j, et al. (2000). Detection of hepatitis C virus RNA in kidney biopsies from infected patients with renal diseases. J viral Hepat; 7:23-29.
[18]
Isaguliants MG. (2003). Hepatitis C virus clearance: the enigma of failure despite an impeccable survival strategy. Curr Pharm Biotechnol; 169-183.
[19]
Matsumori A, Shimada T, Chapman NM, Tracy SM, Mason JW. (2006). Myocarditis and heart failure associated with hepatitis C virus infection.J Card Fail; 12: 293 – 298.
[20]
Siagris D, Christofidou M, Theocharis GJ, et al., (2006). Serum lipid pattern in chronic hepatitis C: histological and virological correlations. J. Viral Hepat. Jan; ; 13: 56–61.
[21]
Dai, CY, Chuang, WL., Hsieh, MY., et al.,(2008).Associations between hepatitis C viremia and low serum triglyceride and cholesterol levels: a community-based study. J Hepatol. Jul; 49(1):9-16.
[22]
Judith I T, Mary A W, Alexander M, et al.,(2009). Association of hepatitis C virus seropositivity with inflammatory markers and heart failure in persons with coronary heart disease. J Card Fail. June; 15(5): 451–456.
[23]
Lao XQ, Thompson A, McHutchison JG, McCarthy JJ (2010). Sex and age differences in lipid response to chronic infection with the hepatitis C virus in the United States National Health and Nutrition Examination Surveys. J Viral Hepat. Jul 19.
[24]
Kaptoge S, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet. 2010; 375(9709):132–140.
[25]
Memon L, Spasojevi-Kalimanovska V, Bogavac-Stanojevi N, et al, (2006). Association of C-reactive protein with the presence and extent of angiographically verified coronary artery disease. Tohoku J Exp Med. Jul; 209(3):197-.
[26]
Huang CF, Hsieh MY, Yang JF, et al., (2010). Serum hs-CRP was correlated with treatment response to pegylated interferon and ribavirin combination therapy in chronic hepatitis C patients. Hepatol Int. Aug 4; 4(3):621-7.
[27]
Lidija PD, Maja J, Miodrag V, et al., (2010). High sensitivity C-reactive protein as prediction factor of disease progression in patients with chronic hepatitis C and mild liver steatosis.Acta Medica. Medianae, Vol.49 (3).
[28]
Nascimento MM, Bruchfeld A, Suliman ME, , et al.(2005).Effect of hepatitis C serology on C-reactive protein in a cohort of Brazilian hemodialysis patients. Braz J Med Biol Res; 38:783 - 788.
[29]
Hashimoto H, Kitagawa K, Hougaku H, Shimizu Y, Sakaguchi M, Nagai Y, et al. (2001).C-reactive protein is an independent predictor of the rate of increase in early carotid atherosclerosis.Circulation; 104:63-67.
[30]
Karantza MV, Mittelman SD, Dorey F, et al., (2008).Relationship of highly sensitive C-reactive protein and lipid levels in adolescents with type 1 diabetes mellitus. Pediatr Diabetes.; 9(2):122-6.
[31]
Sabeti S, Exner M, Mlekusch W, et al.( 2005). Prognostic impact of fibrinogen in carotid atherosclerosis:Nonspecific indicator of inflammation or independent predictor of disease progression? Stroke l; 36: 1400-- 1404.
[32]
Nikolaos P, Dimitris T, Gerasimos S, Christodoulos S (2010). Is fibrinogen a marker of inflammation in coronary artery disease? Hellenic J Cardiol; 51: 1-9.
[33]
Gil M, Zarebi إ „ski M, Olszewski R, Adamus J. (2000).Fibrinogen serum levels in patients with stable coronary artery disease and acute coronary syndrome. Pol Merkur Lekarski. Aug; 9(50):531-2.
[34]
Alyan, O., Kacmaz F., Ozdemir, O., et al., (2008).Hepatitis C infection is associated with increased coronary artery therosclerosis defined by modified Reardon severity score system. Circ J. Dec; 72(12):1960-5.
[35]
Saatea A, Taufeeq A M, Anjum Z, et al., (2006). Serum sialic acid and fibrinogen in complicated and uncomplicated cirrhosis. Journal of Medical Sciences January, Vol. 14, No. 1.
[36]
Tuncer Ö, Selahattin A, Hasan A (2011). Correlation of high sensitive C-reactive protein and Hepatitis C Virus RNA in anti-HCV-positive sera Dicle Tıp Dergisi; 38 (2): 134-136.
[37]
Radkowski M, Wilkinson J, Nowicki M, et al., (2002).Search for hepatitis C virus negative-strand RNA sequences and analysis of viral sequences in the central nervous system: evidence of replication. J Virol. Jan; 76(2):600-8.
[38]
Boddi M, Abbate R, Chellini B, et al., (2010). Hepatitis C virus RNA localization in human carotid plaques. J Clin Virol. Jan; 47(1):72-5.
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186